These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25016399)

  • 21. Resistant hypertension: identifying causes and optimizing treatment regimens.
    Trewet CL; Ernst ME
    South Med J; 2008 Feb; 101(2):166-73. PubMed ID: 18364619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms and treatment of resistant hypertension.
    Pimenta E; Gaddam KK; Oparil S
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):239-44. PubMed ID: 18326968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone-receptor antagonism in hypertension.
    Jansen PM; Danser AH; Imholz BP; van den Meiracker AH
    J Hypertens; 2009 Apr; 27(4):680-91. PubMed ID: 19516169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016.
    Epstein M; Duprez DA
    Am J Med; 2016 Jul; 129(7):661-6. PubMed ID: 26899747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
    Gaddam KK; Pratt-Ubunama MN; Calhoun DA
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
    Schneider A; Schwab J; Karg MV; Kalizki T; Reinold A; Schneider MP; Schmieder RE; Schmidt BM
    J Hypertens; 2017 May; 35(5):1086-1092. PubMed ID: 28118280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.
    Egan BM; Zhao Y; Li J; Brzezinski WA; Todoran TM; Brook RD; Calhoun DA
    Hypertension; 2013 Oct; 62(4):691-7. PubMed ID: 23918752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone and volume management in hypertensive heart disease.
    Sica DA
    Semin Nephrol; 2014 May; 34(3):323-32. PubMed ID: 25016402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistant hypertension and aldosterone: an update.
    Clark D; Ahmed MI; Calhoun DA
    Can J Cardiol; 2012 May; 28(3):318-25. PubMed ID: 22521297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
    Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
    Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation and pharmacologic approach to patients with resistant hypertension.
    Adams M; Bellone JM; Wright BM; Rutecki GW
    Postgrad Med; 2012 Jan; 124(1):74-82. PubMed ID: 22314117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data.
    Shuey M; Perkins B; Nian H; Yu C; Luther JM; Brown N
    BMJ Open; 2020 May; 10(5):e033100. PubMed ID: 32461291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of aldosterone antagonists in the management of resistant hypertension.
    Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension.
    Siddiqui M; Judd EK; Dudenbostel T; Gupta P; Tomaszewski M; Patel P; Oparil S; Calhoun DA
    Hypertension; 2020 Feb; 75(2):510-515. PubMed ID: 31813346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term renal outcomes in patients with primary aldosteronism.
    Sechi LA; Novello M; Lapenna R; Baroselli S; Nadalini E; Colussi GL; Catena C
    JAMA; 2006 Jun; 295(22):2638-45. PubMed ID: 16772627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.
    Sinnott SJ; Tomlinson LA; Root AA; Mathur R; Mansfield KE; Smeeth L; Douglas IJ
    Eur J Prev Cardiol; 2017 Feb; 24(3):228-238. PubMed ID: 27856806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.